EDCTP [to 10 February 2018]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
9 February 2018
Co-infections and co-morbidities: stakeholder meeting report published
Co-infections and co-morbidities in low- and middle-income countries are an important public health problem. These conditions decrease chances of recovery or cure and ultimately result in increased morbidity and mortality. Co-infections present unique challenges in diagnosis, treatment and prevention. Non-communicable diseases (NCDs) have become a fast-growing burden of disease in sub-Saharan Africa. There is a clear need for long-term, more integrated management of poverty-related infectious diseases and NCDs. Therefore, co-infections and co-morbidities are among the priority topics for EDCTP to be addressed in 2018.
Fondation Merieux [to 10 February 2018]
February 8, 2018
Trainings for doctors and laboratory technicians as part of the LABOMEDCAMP project in Mali
February 8, 2018
Congo Republic’s Prime Minister Clément Mouamba visits the Mérieux Foundation to discuss the challenges of infectious diseases in Africa
Gavi [to 10 February 2018]
05 February 2018
Study: vaccines prevent not just disease, but also poverty
New study shows that immunisation in world’s poorest countries is set to save millions from one of the primary causes of extreme poverty: health expenses.
Geneva, 5 February 2018 – In addition to saving millions of lives, vaccines will help prevent 24 million people in some of the world’s poorest countries from slipping into poverty by 2030, according to a study published today in Health Affairs.
The Harvard study, co-authored by Gavi, the Vaccine Alliance and a wide range of partners, modelled the health and economic impact of vaccines for ten diseases in 41 developing countries. As well as the economic impact, the study also estimated that vaccines administered between 2016 and 2030 would prevent 36 million deaths.
“Vaccines don’t just save lives, they also have a huge economic impact on families, communities and economies,” said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. “A healthy child is more likely to go to school and become a more productive member of society in later life, while their families can avoid the often crippling healthcare costs that diseases can bring. As this important study shows, this is enough to save millions of people from the misery of extreme poverty. To realise these figures we now need to redouble our efforts to ensure every child, no matter where they’re born, has access to lifesaving vaccines.”…
Global Fund [to 10 February 2018]
Mozambique and Global Fund Launch New Grants
08 February 2018
The Global Fund and health partners in Mozambique today launched the implementation of six grants aimed at accelerating the end of HIV, tuberculosis and malaria as epidemics.
MSF/Médecins Sans Frontières [to 10 February 2018]
Yemen: Conflict Puts Renal Failure Patients’ Lives at Risk
February 08, 2018
The lives of thousands of renal failure patients are in danger as kidney treatment centers in war-ravaged Yemen close or struggle to function, said the international medical humanitarian organization Doctors Without Borders/Medecins Sans Frontieres (MSF) Thursday.
Zambia: MSF Data Published in New England Journal of Medicine Stresses Effectiveness of Single-Dose Oral Cholera Vaccine
February 07, 2018
data from Zambia’s 2016 cholera epidemic found that giving people just one of the currently-recommended two doses of the oral cholera vaccine was nearly 90 percent effective for adequate short-term protection during this outbreak.
MSF Challenges Pfizer’s Monopoly on Lifesaving Pneumonia Vaccine in South Korea
February 06, 2018
The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) has filed a legal petition to the Supreme Court of South Korea requesting that the court review Pfizer’s patent to for its pneumococcal conjugate vaccine (PCV). On November 29, 2017, the Patent Court of Korea upheld the patent granted to Pfizer for its PCV13 product, marketed as Prevnar13. Unmerited patents like this are a barrier for people, governments, and treatment providers, such as MSF, trying to protect children against pneumonia—a disease that kills almost one million kids every year, or 2,500 per day.
NIH [to 10 February 2018]
February 8, 2018
Ebola virus infects reproductive organs in monkeys
— Additional research is needed to determine if drugs and vaccines can cure or prevent such infections, and to understand the mechanisms of sexual transmission.
PATH [to 10 February 2018]
Press release | February 07, 2018
First vaccine carrier approved by World Health Organization to prevent vaccine freezing during transport commercially available
PATH’s Freeze-Safe innovation sets a new benchmark, helping protect vaccine potency, reducing health worker burden, and providing cost savings to health systems
Announcement | February 06, 2018
Cara Bradley named Chief Corporate Engagement Officer for PATH; Kathryn Kennedy joins as Head of Media
Press release | February 05, 2018
Tackling a silent killer: information and testing for hepatitis C becomes more available in Ho Chi Minh City thanks to integration into community-led services
Ho Chi Minh City, February 5, 2018—People most at risk of contracting hepatitis C virus (HCV), an infectious disease that can result in serious liver damage and death, will soon be able to access more convenient testing options and information about the disease through a new initiative launched today by the Ho Chi Minh City Provincial AIDS Center (HCMC PAC); international non-profit organization, PATH; Gilead Sciences and private clinics in Ho Chi Minh City…
UNAIDS [to 10 February 2018]
Time to act in South Sudan
09 February 2018
A United Nations interagency task team has called for partners, donors, national authorities and others to act in South Sudan.
South Sudan has been ripped apart by civil war for the past two years. Tens of thousands of people have been killed and many others have fled their homes. Widespread reports have detailed looting, rape, enslavement and the use of children in armed conflict.
Two million people are internally displaced in the country and more than 1.95 million people have migrated to neighbouring countries. Food has become scarce and famine has followed.
The task team gives 16 recommendations in a new report, Time to act! Conflict, displacement, famine and the HIV response. Among these are that when targeting food assistance, people living with chronic illnesses, including HIV, should be included, in order to help them to adhere to their treatment. The report also urges the continuing distribution of medicines to treat HIV, sexually transmitted infections and tuberculosis and for condoms to be available through the country and in neighbouring countries.
South Sudan is one of the 38 countries that account for 90% of all new infections, and only 10% of people living with HIV in the country are on life-saving antiretroviral therapy. The conflict has weakened HIV services and host countries often cannot provide for the influx of refugees…
06 February 2018
African first ladies and the African Union launch Free to Shine
First ladies across Africa are spearheading a campaign to stop children acquiring HIV, prevent AIDS-related deaths and keep mothers healthy across Africa.
The Free to Shine campaign was launched by the Organisation of African First Ladies Against HIV/AIDS (OAFLA) and the African Union on the sidelines of the 30th Ordinary Session of the African Union in Addis Ababa, Ethiopia. It was launched during OAFLA’s annual General Assembly, which this year included 20 first ladies from across Africa, joining under the theme of “Transforming Africa through prioritizing children, adolescents and mothers in the fight against HIV”…
UNICEF [to 10 February 2018]
7 February 2018
Violence leaves 750,000 children in Mosul struggling to access basic health services
MOSUL, Iraq, 7 February 2018 – As many as 750,000 children in Mosul and surrounding areas are struggling to access basic health services, UNICEF warned today. While violence has subsided, less than 10 per cent of health facilities in Ninewa governorate are functioning at full capacity, with those that are operational stretched to breaking point.
Three years of intense violence have devastated health facilities in Iraq. Over 60 health facilities have repeatedly come under attack since the escalation of violence in 2014, severely disrupting access to basic health services for children and families.
“The state of Iraq’s healthcare system is alarming. For pregnant women, newborn babies, and children, preventable and treatable conditions can quickly escalate into a matter of life and death,” said Peter Hawkins, UNICEF Representative in Iraq, who has just completed a visit to Al Khansa hospital in Mosul, the largest in the city. “Medical facilities are strained beyond capacity and there are critical shortages of life-saving medicines.”
UNICEF has stepped up its support to primary healthcare facilities to help the Government of Iraq provide critical health services so that children and families affected by violence and displacement can resume their lives.
In Mosul, UNICEF has rehabilitated the pediatric and nutritional wards of two hospital centres, provided refrigerators to store vaccines for up to 250,000 children, and supported vaccination campaigns to immunize all children under five years old. Most health centres in the governorate have also restarted vaccination services for children.
“As people start to return to their homes, it is essential that basic services like health, education, and specialized support for children impacted by violence are available,” said Hawkins…
Vaccine Education Center – Children’s Hospital of Philadelphia [to 10 February 2018]
Published on Feb 07, 2018
New Shingles Vaccine Changes Recommendations for Adults
In this video, Dr. Offit discusses the differences between the two shingles vaccines and updated recommendations for adults. These include getting the vaccine at 50 years of age instead of 60 and being revaccinated if you’ve previously received the older version (Zostavax).
Wellcome Trust [to 10 February 2018]
News / Published: 6 February 2018
£10 million to fund new urban health project in ten cities
Wellcome is launching a £10 million research partnership across four continents to help improve understanding of how countries can create healthier cities and protect the planet.
The partnership is a network of experts from science and other disciplines working closely with ten cities around the world. It will be led by Mike Davies, Professor of Building Physics and Environment at University College London, and Majid Ezzati, Professor of Global Environmental Health at Imperial College London.
The aim is to provide evidence to help policy makers and governments act to improve population health and protect the planet in a way that minimises health inequality.
The cities involved are: London (UK), Rennes (France), Beijing and Ningbo (China), Nairobi and Kisumu (Kenya), Dhaka (Bangladesh), Vancouver (Canada), and Accra and Tamale (Ghana)…
News / Published: 22 January 2018
New Wellcome office in Berlin will bolster global partnerships
News / Published: 22 January 2018
Wellcome is planning to open a small office in the German capital later this year so that we can work more closely with our international partners on shared priorities…
BIO [to 10 February 2018]
Feb 9 2018
BIO Applauds Introduction of the Vaccine Access Improvement Act
Washington, DC (February 9, 2018) – – The Biotechnology Innovation Organization (BIO) applauds Reps. Mike Kelly (R-PA) and Brian Higgins (D-NY) for introducing H.R. 4993, the Vaccine Access Improvement Act, which would promote timely access to new first-in-class childhood and maternal vaccines. The legislation would update the tax code to ensure new first-in-class vaccines are promptly covered under the National Vaccine Injury Compensation Program (VICP).
The VICP was created by the National Childhood Vaccine Injury Act (NCVIA) of 1986 and serves as a no-fault alternative to the traditional legal system for resolving vaccine injury petitions. The program is funded by an excise tax paid by manufacturers on each vaccine. Under current law, new first-in-class vaccines may only be added to the program by changing the underlying tax statute to include the disease that the vaccine protects against. The Vaccine Access Improvement Act would streamline this process by giving the Secretary of Health and Human Services regulatory authority to add new eligible vaccines to the program once they have been approved by the FDA and recommended by the CDC.
“Updating the Vaccine Injury Compensation Program to allow for the prompt inclusion of new childhood and maternal vaccines is crucial to ensuring timely access to these life-saving preventative medicines,” said BIO President and CEO Jim Greenwood. “I commend Reps. Kelly and Higgins for their efforts to protect our nation’s mothers and children.”…